Company intelligence / Profile preview

G-Ex Technologies

Chiyoda-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

G-Ex is a Japanese biotechnology company specializing in the development of exosome-based diagnostics and therapeutics. Founded as a spin-off from research at the National Cancer Center and Tokyo Medical University, the company leverages a proprietary platform for the high-purity isolation and analysis of extracellular vesicles (EVs). Their primary focus is on liquid biopsy applications for early cancer detection and the development of exosome-mediated drug delivery systems. G-Ex aims to standardize exosome analysis to enable precision medicine and improve patient outcomes in oncology and other therapeutic areas.

Therapeutic areas: Oncology
Modalities: Exosome-based therapyLiquid biopsy
Industry: Biotech

Partnerships

National Cancer Center JapanTokyo Medical University

Beyond the preview

Go deeper on G-Ex Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G-Ex Technologies.

Explore the full profile